Contents lists available at ScienceDirect



Respiratory Physiology & Neurobiology

journal homepage: www.elsevier.com/locate/resphysiol

Short communication

Low exertional inspiratory capacity is not related to dynamic inspiratory muscle weakness in heart failure



Franciele Plachi, Fernanda Machado Balzan, Ricardo Gass, Rui Gustavo Dorneles, Reisi Zambiazi, Danton Pereira da Silva, Paulo R. Sanches, Nadine Oliveira Clausell, Danilo C. Berton*

Universidade Federal do Rio Grande do Sul (UFRGS) & Hospital de Clinicas de Porto Alegre (HCPA), Porto Alegre, RS, Brazil

ARTICLE INFO	A B S T R A C T
<i>Keywords:</i> Exercise test Respiratory mechanics Respiratory muscles Heart failure Dyspnea Hyperinflation	Reduction in inspiratory capacity (IC) during exercise has been reported in chronic heart failure (CHF). Since inspiratory muscle dysfunction may be present to a variable degree, the assumption that IC reduction during exercise represents an increase in end-expiratory lung volume must be made with caution. This interpretation is flawed if patients develop dynamic inspiratory muscle strength reduction, i.e., progressively lower esophageal (Pes) pressures as the IC maneuvers are repeated. Sixteen CHF patients and 9 age-matched controls performed an incremental exercise test with serial IC and respiratory pressure measurements. Regardless whether IC decreased or not with exercise (N = 4 and N = 12, respectively), Pes,IC remained stable. This was confirmed by similar Pes,sniff immediately upon exercise cessation ($p > .05$). No association was found between changes in IC and related Pes from rest to peak exercise. Owing to the lack of dynamic inspiratory muscle weakness, non-invasive indexes of lung mechanics can be reliably obtained from exercise IC in CHF.

1. Introduction

Reduction in inspiratory capacity (IC) during exercise has been described across the spectrum of chronic heart failure (CHF) severity, being inversely correlated to peak aerobic capacity (Papazachou et al., 2007). The IC represents the true operating limits for tidal volume (V_T) expansion during exercise and importantly influences breathing patterns and peak ventilatory capacity (Guenette et al., 2013). Interestingly, improving cardiac function by cardiac resynchronization resulted in higher IC and lower dyspnea during exercise in these patients (Laveneziana et al., 1985)

Exercise-induced reduction in IC, however, may be secondary to high end-expiratory lung volume (dynamic hyperinflation) if total lung capacity (TLC) is consistently reached at end-inspiration (Guenette et al., 2013); alternatively, a low IC might merely reflect failure to reach TLC due to progressive impairment in inspiratory muscle strength or poor effort as exercise progresses (Langer et al., 2014). Patients with heart failure show reduced resting static lung compliance associated with either restrictive or obstructive ventilatory patterns on resting lung function, thus increasing the propensity for expiratory airflow limitation. Heart failure patients with resting expiratory flow limitation have been shown to decrease dynamic IC in the setting of increased ventilatory demand of exercise (Dubé et al., 2016). The other hypothesis is particularly concerning in CHF, a patient population in which inspiratory muscle weakness is prevalent (Evans et al., 1995; Hughes et al., 1999) and parallels exertional dyspnea and functional deterioration (Mancini et al., 1992; Kasahara et al., 2015).

Dynamic respiratory mechanics, however, has never been extensively studied in CHF (Guenette et al., 2013; Dubé et al., 2016). The aim of the present study, therefore, was to investigate the behavior of dynamic inspiratory muscle strength according to the presence or absence of IC reduction during exercise in patients with CHF and compare with healthy controls.

2. Methods

2.1. Study population

We recruited stable, non-obese patients with clinical diagnosis of CHF and left ventricular ejection fraction < 45% by echocardiography. Subjects matched for sex and age were recruited from the community to serve as healthy controls. Exclusion criteria included forced expiratory volume in 1s/forced vital capacity below the lower limit of normal (LLN), and any other disorder potentially contributing to impaired exercise capacity. Ethical approval was obtained from the Institutional Ethics Committee (N° 14-0512) and all subjects signed written informed consent.

https://doi.org/10.1016/j.resp.2018.04.005 Received 11 February 2018; Received in revised form 11 April 2018; Accepted 14 April 2018 Available online 16 April 2018 1569-9048/ © 2018 Elsevier B.V. All rights reserved.

^{*} Corresponding author at: Rua Ramiro Barcelos, 2350, Room 2050, Postal Code: 90035-003, Porto Alegre, RS, Brazil. *E-mail address*: dberton@hcpa.edu.br (D.C. Berton).

Characteristics of studied participants.

Age, yrs 59 ± 9 56 ± 12 Male:Female, n11.56.3Height, m16.6 ± 1116.4 ± 10BMI, kg/m ² 25.7 ± 3.424.7 ± 3.1Smoker: current/former/never27.7707.1/8Smoking burden, pack-yrs53 ± 3126'Modified MRC dyspnea scale, 0-40.8 ± 0.80 ± 0'NVHA functional classification, n (%)I13 (81)II3 (19)Chronic heart failure etiology, n(%)Kishemic cardiomyopathy9 (56)-Ischemic cardiomyopathy1 (6)-Holpathic cardiomyopathy1 (6)-Hypertensive cardiomyopathy1 (6)-Holpathic cardiomyopathy1 (6)-Holpathic cardiomyopathy1 (6)-Holpathic scale (and on statistic converting enzyme inhibitors10 (63)0 (0)'Angiotensin-converting enzyme inhibitors10 (63)0 (0)'Diuretics10 (63)0 (0)'Diuretics0 (63)0 (0)'Diuretics10 (63)0 (0)'PW, L (% pred)2.52 ± 0.74 (82 ± 19)2.51 ± 0.56 (98 ± 15)'FVC, L (% pred)2.52 ± 0.74 (82 ± 19)2.51 ± 0.56 (98 ± 15)'FVC, L (% pred)2.52 ± 0.74 (82 ± 19)2.51 ± 0.56 (98 ± 15)'FVC, C (%)81 ± 879 ± 2FW, rSVC, (%)81 ± 879 ± 2FW, rSVC, (%)81 ± 879 ± 2FW, rSVC, (%)5.75 ± 1.39 (67 ± 11)6.54 ± 0.5	Variable	CHF (n = 16)	Controls $(n = 9)$		
Height cm165 ± 11164 ± 10BMI, kg/m225.7 ± 3.424.7 ± 3.1Smoker: current/former/never27.770/1/8Smoking burden, pack-yrs53 ± 3126'Modified MRC dyspnes acale, 0-40.8 ± 0.80 ± 0'NTHA functional classification, n (%)I13 (81)II3 (19)Chronic heart failure etiology, n (%)Ischemic cardiomyopathy9 (56)-Alcoholic cardiomyopathy1 (6)-Alcoholic cardiomyopathy1 (6)-Alcoholic cardiomyopathy1 (6)-Alcoholic cardiomyopathy1 (6)-Angiotensin-converting enzyme inhibitors10 (63)0 (0)'Angiotensin-converting enzyme inhibitors10 (63)0 (0)'Diuretics0 (63)0 (0)'Diuretics10 (63)0 (0)'Putmoary FunctionFEV, 1 (% pred)2.52 ± 0.74 (82 ± 19)2.54 ± 0.56 (98 ± 8)'FEV, FVC, (%)82 ± 781 ± 2FEV_VSC, (%)81 ± 879 ± 2FEV_VSC, (%)81 ± 879 ± 2FEV_VSC, (%)11 ± 0.97 (64 ± 15)5.76 ± 0.81 (109 ± 10)'SC, L (% pred)2.54 ± 0.97 (83 ± 39)2.65 ± 0.65 (98 ± 15)TC, L (% pred)2.38 ± 0.64 (130 ± 38)2.99 ± 0.44 (00 ± 63)'FEV_VSC, (%)81 ± 879 ± 2FEV_SC, (% pred)2.38 ± 0.64 (130 ± 38)2.09 ± 0.44 (00 ± 63)'TC, L (% pred)2.57 ± 1.	Age, yrs	59 ± 9	56 ± 12		
BM, kg/m ² 25.7 ± 3.4 24.7 ± 3.1 Smoker: current/former/never $2/7/7$ $0.1/8$ Smoking burden, pack-yrs 53 ± 31 26° Modified MRC dyspnea scale, $0-4$ 0.8 ± 0.8 $0 \pm 0^{\circ}$ NYHA functional classification, n (%) 1 $13 (81)$ $-$ I $3 (19)$ $ -$ Idiopathic cardiomyopathy $9 (56)$ $ -$ Ischemic cardiomyopathy $1 (6)$ $ -$ Idiopathic cardiomyopathy $1 (6)$ $ -$ Hypertensive cardiomyopathy $1 (6)$ $ -$ Hedication, $n (%)$ $ -$ Beta-blockers $15 (94)$ $1 (6)^{\circ}$ $-$ Angiotensin I receptor antagonist $4 (25)$ $0 (0)^{\circ}$ $-$ Pulmoary Function $ -$ FEV, $1, (% pred)$ $252 \pm 0.74 (82 \pm 19)$ $2.81 \pm 0.56 (98 \pm 8)^{\circ}$ $-$ FV, $1, (\% pred)$ $3.08 \pm 0.88 (79 \pm 16)$ $3.48 \pm 0.70 (97 \pm 8)^{\circ}$ $-$ FEV, $1, (\% pred)$ $2.54 \pm 0.97 (83 \pm $	Male:Female, n	11:5	6:3		
Snoker 27.7 0.1/8 Smoking burden, pack-yrs 53 ± 31 26° Modified MRC dyspnes acale, 0-4 0.8 ± 0.8 0.± 0° NYHA functional classification, n (%) - - I 13 (81) - Bit 3 (19) - Chronic heart failure etiology, n (%) - - Idepathic cardiomyopathy 9 (56) - Alcoholic cardiomyopathy 1 (6) - Hypertensive cardiomyopathy 1 (6) - Hypertensive cardiomyopathy 1 (6) - Medication, n (%) E - Beta-blockers 1 (63) 0 (0)^{'} Angiotensin-converting enzyme inhibitors 10 (63) 0 (0)^{'} Diuretics 10 (63) 0 (0)^{'} Diuretics 3.08 ± 0.88 (79 ± 16) 3.48 ± 0.70 (97 ± 8)^{'} FEV, L (% pred) 2.52 ± 0.74 (82 ± 19) 2.51 ± 0.56 (98 ± 8)^{'} FV, L (% pred) 2.54 ± 0.97 (83 ± 39) 2.65 ± 0.68 (98 ± 15) FV, L (% pred) 3.08 ± 0.88 (79 ± 16) 3.48 ± 0.70 (97	Height, cm	165 ± 11	164 ± 10		
Snoking burden, pack-yrs 53 ± 31 26° Modified MRC dyspnea scale, 0-4 0.8 ± 0.8 0.2 ± 0° NYHA functional classification, n (%) 1 13 (81) - I 13 (81) - - II 3 (19) - - Chronic heart failure etiology, n (%) - - - Idiopathic cardiomyopathy 9 (56) - - Alcoholic cardiomyopathy 1 (6) - - Alcoholic cardiomyopathy 1 (6) - - Hypertensive cardiomyopathy 1 (6) - - Alcoholic cardiomyopathy 1 (6) - - Angiotensin Ir ceeptor antagonist 10 (63) 0 (0)' - Aldosterone receptor antagonist 9 (56) 0 (0)' - Pulmoary Function - 81 ± 2 2 - FEV, r/, V(% (%) 81 ± 8 79 ± 2 - - - Pulmoary Function - - - - -	BMI, kg/m ²	25.7 ± 3.4	24.7 ± 3.1		
Modified MRC dyspnes scale, 0-4 0.8 ± 0.8 $0 \pm 0^{\circ}$ NTHA functional classification, n (%) I I 13 (81) - II 3 (19) - Chronic heart failure etiology, n (%) - - Idiopathic cardiomyopathy 9 (56) - Ischemic cardiomyopathy 4 (26) - Alcoholic cardiomyopathy 1 (6) - Hypertensive cardiomyopathy 1 (6) - Endomyocardial fibrosis 15 (94) 1 (6)^{\circ} Angiotensin-converting enzyme inhibitors 10 (63) 0 (0)^{\circ} Angiotensin-converting enzyme inhibitors 10 (63) 0 (0)^{\circ} Dituretics 10 (63) 0 (0)^{\circ} Pulmonary Function - FEV ₁ , L (% pred) 2.52 ± 0.74 (82 ± 19) 2.81 ± 0.56 (98 ± 8)^{\circ} FEV ₂ , L (% pred) 8.2 ± 7 81 ± 2 FEV ₂ , L (% pred) 2.52 ± 0.74 (82 ± 19) 2.81 ± 0.56 (98 ± 15) S7C, L (% pred) 8.2 ± 7 81 ± 2 FEV ₂ , L (% pred) 2.54 ± 0.97 (83 ± 39) 2.65 ± 0.65 (98 ± 15) S7C, L (% pred) 2.54 ± 0.97 (81 ± 39)			-, , -		
NYHA functional classification, n (%) 1 13 (81) - I 3 (19) - Chronic heart failure etiology, n (%) - - Idiopathic cardiomyopathy 9 (56) - Ischemic cardiomyopathy 4 (26) - Alcoholic cardiomyopathy 1 (6) - Hypertensive cardiomyopathy 1 (6) - Medication, n (%) - - Beta-blockers 15 (94) 1 (6)^* Angiotensin I receptor antagonist 9 (56) 0 (0)^* Angiotensin I receptor antagonist 9 (56) 0 (0)^* Diuretics 10 (63) 0 (0)^* Pulmoary Function - - FEV, I, L (% pred) 2.52 ± 0.74 (82 ± 19) 2.81 ± 0.56 (98 ± 8)^* FVC, L (% pred) 3.08 ± 0.38 (79 ± 16) 3.48 ± 0.70 (97 ± 8)^* FEV, SVC, (%) 82 ± 7 81 ± 2 FEV, SVC, (%) 82 ± 7 81 ± 2 FEV ₂ , SVC, (%) 81 ± 8 79 ± 2 FET _{25-75%4} L.S ⁻¹ (% pred) 2.54 ± 0.97 (83 ± 39) 2.65 ± 0.65 (98 ± 15) ST/C, L (% pred) 2.16 ± 0.97 (81 ± 39)	0 ,1 ,				
I13 (81) 3 (19)-I13 (81) 3 (19)-I103 (19)-Chronic heart failure etiology, n (%)Idiopathic cardiomyopathy9 (56)-Ischemic cardiomyopathy4 (26)-Alcoholic cardiomyopathy1 (6)-Alcoholic cardiomyopathy1 (6)-Medication, n (%)-Beta-blockers15 (94)1 (6)^'Angiotensin-converting enzyme inhibitors10 (63)0 (0)'Angiotensin-converting enzyme inhibitors10 (63)0 (0)'Diuretics10 (63)0 (0)'Diuretics10 (63)0 (0)'Diuretics10 (63)0 (0)'Diuretics10 (63)0 (0)'Petv, L (% pred)2.51 ± 0.74 (82 ± 19)2.81 ± 0.56 (98 ± 8)'FEV, /VC, (%)82 ± 781 ± 2FEV, /VC, (%)81 ± 879 ± 2FEF2 _{25-75%0} Ls ⁻¹ (% pred)2.64 ± 0.97 (83 ± 39)2.65 ± 0.65 (98 ± 15)TLC, L (% pred)2.84 ± 0.87 (87 ± 18)2.60 ± 0.53 (102 ± 24)'SVC, L (% pred)2.54 ± 0.81 (87 ± 18)2.60 ± 0.53 (102 ± 24)'FEV, /VC, (%)2.34 ± 0.67 (91 ± 18)3.01 ± 0.54 (77 ± 46)RV, L (% pred)2.34 ± 0.67 (91 ± 18)3.01 ± 0.54 (77 ± 46)RV, L (% pred)2.34 ± 0.67 (91 ± 18)3.01 ± 0.54 (77 ± 46)RV, L (% pred)129 ± 24106 ± 13'DLCO, (mmol/min/RPa/L)118 ± 0.23 (81 ± 14)2.17 ± 1.15 (66 ± 11)DLCO, (mmol/min/RPa/L)118 ± 0.23 (81 ± 1	Modified MRC dyspnea scale, 0-4	0.8 ± 0.8	$0 \pm 0^{*}$		
II $3(19)$ -Chronic heart failure etiology, n (%)-Idiopathic cardiomyopathy9 (56)-Ischemic cardiomyopathy1 (6)-Alcoholic cardiomyopathy1 (6)-Hypertensive cardiomyopathy1 (6)-Endomyocardial fibrosis1 (6)-Beta-blockers1 (6)-Angiotensin-converting enzyme inhibitors10 (63)0 (0)^*Angiotensin If receptor antagonist4 (25)1 (6)Angiotensin If receptor antagonist9 (56)0 (0)^*Diuretics10 (63)0 (0)*Diuretics10 (63)0 (0)*Pulmonary FunctionEEFEV, L (% pred)2.52 ± 0.74 (82 ± 19)2.81 ± 0.56 (98 ± 8)*FVV, C (%)81 ± 879 ± 2FEV, SVC, (%)81 ± 879 ± 2FEF2, SVSC, (%)81 ± 879 ± 2FEF2, SVSC, (%)5.54 ± 0.97 (83 ± 39)2.65 ± 0.65 (98 ± 15)SVC, L (% pred)2.54 ± 0.67 (91 ± 18)3.01 ± 0.54 (109 ± 10)*SVC, L (% pred)2.54 ± 0.67 (91 ± 18)3.01 ± 0.54 (109 ± 10)*SVC, L (% pred)2.54 ± 0.61 (87 ± 18)2.06 ± 0.53 (102 ± 24)*RVT, L (% pred)2.54 ± 0.51 (87 ± 11)5.57 ± 1.39 (67 ± 11)SVC, L (% pred)2.54 ± 0.67 (91 ± 18)3.01 ± 0.54 (109 ± 10)*SVC, L (% pred)2.54 ± 0.51 (87 ± 11)1.54 ± 1.24 (79 ± 11)DLCO, (mon/min/kPa)129 ± 24106 ± 13*DLCO, (mon/min/kPa)129 ± 24106 ± 13*DLCO, (mon/min/kPa/L)					
Chronic heart failure etiology, n (%)-Idiopathic cardiomyopathy9 (56)-Ischemic cardiomyopathy4 (26)-Alcoholic cardiomyopathy1 (6)-Hypertensive cardiomyopathy1 (6)-Endomyocardial fibrosis1 (6)-Medication, 0%)Beta-blockers15 (94)1 (6) [*] Angiotensin-converting enzyme inhibitors10 (63)0 (0) [*] Angiotensin-converting enzyme inhibitors10 (63)0 (0) [*] Diuretics10 (63)0 (0) [*] Pumoary FunctionFEV, L (% pred)2.52 \pm 0.74 (82 \pm 19)2.81 \pm 0.56 (98 \pm 8) [*] FVC, L (% pred)3.08 \pm 0.88 (79 \pm 16)3.48 \pm 0.70 (97 \pm 8)FEV, J/VC, (%)82 \pm 781 \pm 2FFE _{25,7596} , Ls ⁻¹ (% pred)2.54 \pm 0.97 (83 \pm 39)2.65 \pm 0.65 (98 \pm 15)TLC, L (% pred)5.44 \pm 1.27 (96 \pm 15)5.76 \pm 0.81 (109 \pm 10) [*] SVC, L (% pred)2.54 \pm 0.97 (83 \pm 39)2.65 \pm 0.65 (98 \pm 15)TLC, (% pred)2.54 \pm 0.81 (87 \pm 18)2.60 \pm 0.53 (102 \pm 24) [*] FK, L (% pred)2.54 \pm 0.81 (87 \pm 18)2.60 \pm 0.53 (102 \pm 24) [*] FR, L (% pred)2.94 \pm 0.64 (130 \pm 38)2.09 \pm 0.44 (90 \pm 63)RV/ LC, (% pred) <td></td> <td></td> <td>-</td>			-		
Idiopathic cardiomyopathy9 (56)-Ischemic cardiomyopathy4 (26)-Alcoholic cardiomyopathy1 (6)-Hypertensive cardiomyopathy1 (6)-Endomyocardial fibrosis1 (6)-Medication, n (%)Beta-blockers15 (94)1 (6)^^{'}Angiotensin-converting enzyme inhibitors10 (63)0 (0)^{'}Angiotensin II receptor antagonist4 (25)1 (6Aldosterone receptor antagonist9 (56)0 (0)^{'}Diuretics10 (63)0 (0)^{'}Pulmonary FunctionFEV1, L (% pred)2.52 ± 0.74 (82 ± 19)2.81 ± 0.56 (98 ± 8)^{'}FEV2, L (% pred)3.06 ± 0.88 (79 ± 16)3.48 ± 0.70 (97 ± 8)^{'}FEV1, FVC, (%)82 ± 781 ± 2FEV1, FVC, (%)81 ± 879 ± 2FEF25, ST-98, Ls-1^{'} (% pred)2.54 ± 0.97 (83 ± 39)2.65 ± 0.65 (98 ± 15)^{'}STC, L (% pred)3.10 ± 0.95 (84 ± 23)3.54 ± 0.71 (105 ± 7)^{'}SV, L (% pred)2.54 ± 0.67 (91 ± 18)3.01 ± 0.54 (77 ± 46)^{'}RV/TLC, (% pred)2.38 ± 0.64 (130 ± 38)2.09 ± 0.44 (90 ± 63)^{'}RV/TLC, (% pred)2.38 ± 0.64 (130 ± 38)2.09 ± 0.44 (90 ± 63)^{'}RV/TLC, (% pred)1.18 ± 0.23 (81 ± 14)2.17 ± 1.15 (86 ± 11)PLOO, (mml-min/kPa/L)1.18 ± 0.23 (81 ± 14)2.17 ± 1.15 (86 ± 11)PLOO, (mml-Min/kPa/L)1.18 ± 0.23 (81 ± 14)2.17 ± 1.15 (86 ± 11)PLOO, (mml-Min/kPa/L)1.18 ± 0.23 (81 ± 14)2.17 ± 1.15 (86 ± 11) <td>11</td> <td>3 (19)</td> <td>-</td>	11	3 (19)	-		
Ischemic cardiomyopathy4 (26)-Alcoholic cardiomyopathy1 (6)-Hypertensive cardiomyopathy1 (6)-Endomyocardial fibrosis1 (6)-Medication, n (%)1 (6)-Beta-blockers15 (94)1 (6)^{'}Angiotensin-converting enzyme inhibitors10 (63)0 (0)^{'}Angiotensin II receptor antagonist4 (25)1 (6)Aldosterone receptor antagonist9 (56)0 (0)^{'}Dilorensin II receptor antagonist9 (56)0 (0)^{'}Pulmonary FunctionFEV1, I. (% pred)2.52 \pm 0.74 (82 \pm 19)2.81 \pm 0.56 (98 \pm 8)'FEV2, I. (% pred)3.08 \pm 0.88 (79 \pm 16)3.48 \pm 0.70 (97 \pm 8)'FEV1, VPC, (%)81 \pm 879 \pm 2FEF225-75% Ls ⁻¹ (% pred)2.54 \pm 0.97 (83 \pm 39)2.65 \pm 0.65 (98 \pm 15)TLC, L (% pred)3.10 \pm 0.95 (84 \pm 23)3.54 \pm 0.71 (105 \pm 7)'SVC, L (% pred)2.54 \pm 0.67 (91 \pm 18)2.60 \pm 0.53 (102 \pm 24)'FRC, L (% pred)2.94 \pm 0.67 (91 \pm 18)3.01 \pm 0.54 (77 \pm 46)RV/ LC (% pred)2.95 \pm 1.39 (67 \pm 11)6.54 \pm 1.42 (79 \pm 11)DLCO, (Mmol/min/kPa)5.57 \pm 1.39 (67 \pm 11)6.54 \pm 1.42 (79 \pm 11)DLCO, VA (mmol/min/kPa/L)1.13 \pm 42130 \pm 49HVP, cmH2O-67 \pm 18-73 \pm 17MIP, cmH2O-67 \pm 18-73 \pm 17MIP, cmH2O-67 \pm 18-142 (79 \pm 11)DLCO, VA (mond/min/kPa/L)1.13 \pm 42130 \pm			-		
Alcoholic cardiomyopathy1 (6)-Hypertensive cardiomyopathy1 (6)-Endomyocardial fibrosis1 (6)-Medication, n (%)1(6)Beta-blockers15 (94)1 (6)Angiotensin-converting enzyme inhibitors10 (63)0 (0)Angiotensin converting enzyme inhibitors10 (63)0 (0)Angiotensin converting enzyme inhibitors10 (63)0 (0)Diuretics0 (0)0 (0)Diuretics10 (63)0 (0)Puttores0 (0)0 (0)Puttores0 (6)0 (0)Puttores0 (6)0 (0)Puttores0 (6)0 (0)Puttores0 (6)0 (6) <td></td> <td></td> <td>-</td>			-		
Hypertensive cardiomyopathy1 (6)-Endomyocardial fibrosis1 (6)-Medication, n (%)-Beta-blockers15 (94)1 (6)°Angiotensin-converting enzyme inhibitors10 (63)0 (0)°Angiotensin II receptor antagonist4 (25)1 (6)Aldosterone receptor antagonist9 (56)0 (0)°Diuretics10 (63)0 (0)°Pulmoary FunctionFEV, L (% pred)2.52 \pm 0.74 (82 \pm 19)2.81 \pm 0.56 (98 \pm 8)°FVC, L (% pred)2.52 \pm 0.74 (82 \pm 19)2.81 \pm 0.56 (98 \pm 8)°FVV, L (% pred)82 \pm 781 \pm 2FEV_3/KVC, (%)81 \pm 879 \pm 2FEV_5/KVC, (%)81 \pm 879 \pm 2FEV_5/SWS, Ls ⁻¹ (% pred)2.54 \pm 0.97 (83 \pm 39)2.65 \pm 0.65 (98 \pm 15)TLC, L (% pred)3.10 \pm 0.57 (84 \pm 23)3.54 \pm 0.71 (105 \pm 7)°IC, L (% pred)2.54 \pm 0.81 (87 \pm 18)2.60 \pm 0.53 (102 \pm 24)°FRC, L (% pred)2.94 \pm 0.67 (91 \pm 18)3.01 \pm 0.54 (109 \pm 63)°RV/TLC, (% pred)129 \pm 24106 \pm 13°DLCO/VA (mnol/min/kPa)5.57 \pm 1.39 (67 \pm 11)6.54 \pm 1.42 (79 \pm 11)DLCO/VA (mnol/min/kPa/L)118 \pm 0.23 (81 \pm 14)2.17 \pm 1.15 (86 \pm 11)Pes hift, cmH ₂ O-67 \pm 18-73 \pm 17MIP, cmH ₂ O-76 \pm 28-97 \pm 16MIP, cmH ₂ O-76 \pm 28-97 \pm 16MIP, cmH ₂ O-76 \pm 28-97 \pm 16MIP, cmH ₂ O-76 \pm 2			-		
Endomyocardial fibrois1 (6)-Medication, n (%)			-		
Medication, n (%)Beta-blockers15 (94)1 (6)Angiotensin-converting enzyme inhibitors10 (63)0 (0)Angiotensin II receptor antagonist4 (25)1 (6)Aldosterone receptor antagonist9 (56)0 (0)Diuretics10 (63)0 (0)Pulmonary FunctionFEV, I, L (% pred)2.52 ± 0.74 (82 ± 19)2.81 ± 0.56 (98 ± 8)FVC, L (% pred)2.52 ± 0.74 (82 ± 19)2.81 ± 0.56 (98 ± 8)FVC, L (% pred)8.088 (79 ± 16)3.48 ± 0.70 (97 ± 8)FEV, FVC, (%)81 ± 879 ± 2FEV, JCVC, (%)81 ± 879 ± 2FEV, JCVC, (%)81 ± 879 ± 2FEF_2, 75%, Ls ⁻¹ (% pred)2.54 ± 0.97 (83 ± 39)2.65 ± 0.65 (98 ± 15)SVC, L (% pred)5.48 ± 1.27 (96 ± 15)5.76 ± 0.81 (109 ± 10)SVC, L (% pred)2.54 ± 0.81 (87 ± 18)2.60 ± 0.53 (102 ± 24)FRC, L (% pred)2.54 ± 0.81 (87 ± 18)3.01 ± 0.54 (77 ± 46)RV, L (% pred)2.38 ± 0.64 (130 ± 38)2.09 ± 0.44 (90 ± 63)RV/TLC, (% pred)1.29 ± 24106 ± 13°DLCOVA (mmol/min/kPa)5.57 ± 1.39 (67 ± 11)6.54 ± 1.42 (79 ± 11)DLCOVA (mmol/min/kPa/L)1.18 ± 0.23 (81 ± 14)2.17 ± 1.15 (86 ± 11)Pes snift, cmH_2O -67 ± 18 -73 ± 17 MP, cmH_2O -76 ± 28 -97 ± 16 MEP, cmH_2O -67 ± 18 -73 ± 17 MP, cmH_2O -76 ± 28 -97 ± 16 MEP, cmH_2O -76 ± 28 -97 ± 16 MEP, cmH_2O -67 ± 18	51 51 5		-		
Beta-blockers15 (94)1 (6)°Angiotensin-converting enzyme inhibitors10 (63)0 (0)°Angiotensin II receptor antagonist4 (25)1 (6)Aldosterone receptor antagonist9 (56)0 (0)°Diuretics10 (63)0 (0)°Pulmonary FunctionFEV1, L (% pred)2.52 \pm 0.74 (82 \pm 19)2.81 \pm 0.56 (98 \pm 8)°FVC, L (% pred)3.08 \pm 0.88 (79 \pm 16)3.48 \pm 0.70 (97 \pm 8)°FEV1/SVC, (%)81 \pm 879 \pm 2FEF2 _{25-75%0} L.s ⁻¹ (% pred)2.54 \pm 0.97 (83 \pm 39)2.65 \pm 0.65 (98 \pm 15)TLC, L (% pred)2.54 \pm 0.97 (83 \pm 39)2.65 \pm 0.65 (98 \pm 15)TLC, L (% pred)3.10 \pm 0.95 (84 \pm 23)3.54 \pm 0.71 (105 \pm 7)°TLC, L (% pred)2.54 \pm 0.67 (91 \pm 18)2.60 \pm 0.53 (102 \pm 24)°FRC, L (% pred)2.94 \pm 0.67 (91 \pm 18)3.01 \pm 0.54 (77 \pm 46)RV/TLC, (% pred)129 \pm 24106 \pm 13°DLCO, (mmol/min/kPa)5.57 \pm 1.39 (67 \pm 11)6.54 \pm 1.42 (79 \pm 11)DLCO, VA (mmol/min/kPa/L)1.18 \pm 0.23 (81 \pm 14)2.17 \pm 1.15 (86 \pm 11)Pes Sniff, cmH2O-67 \pm 18-73 \pm 17MIP, cmH2O113 \pm 42130 \pm 49CehcoardiogramLVEF, %31 \pm 6-LV end-diastolic volume, mL208.7 \pm 44.5-LV end-diastolic volume, mL208.7 \pm 45.9-LV end-diastolic volume, mL208.7 \pm 44.5-LV end-diastolic volume, mL208.7 \pm 45.9- <td>Endomyocardial fibrosis</td> <td>1 (6)</td> <td>-</td>	Endomyocardial fibrosis	1 (6)	-		
Angiotensin-converting enzyme inhibitors10 (63)0 (0°Angiotensin II receptor antagonist4 (25)1 (6)Aldosterone receptor antagonist9 (56)0 (0°Diuretics10 (63)0 (0°Pulmonary FunctionFEV1, L (% pred)2.52 \pm 0.74 (82 \pm 19)2.81 \pm 0.56 (98 \pm 8)°FVC, L (% pred)3.08 \pm 0.88 (79 \pm 16)3.48 \pm 0.70 (97 \pm 8)°FEV1/FVC, (%)82 \pm 781 \pm 2FEV2/SVC, (%)81 \pm 879 \pm 2FEF3_25.75% L.5 ⁻¹ (% pred)2.54 \pm 0.97 (83 \pm 39)2.65 \pm 0.65 (98 \pm 15)TLC, L (% pred)3.10 \pm 0.97 (83 \pm 23)3.54 \pm 0.71 (105 \pm 70)°SVC, L (% pred)3.10 \pm 0.97 (81 \pm 23)3.54 \pm 0.71 (105 \pm 70)°SVC, L (% pred)2.54 \pm 0.67 (91 \pm 18)2.60 \pm 0.53 (102 \pm 24)°FRC, L (% pred)2.94 \pm 0.67 (91 \pm 18)3.01 \pm 0.54 (77 \pm 46)RV, L (% pred)1.29 \pm 24106 \pm 13°DLCO, (mond/min/kPa)5.57 \pm 1.39 (67 \pm 11)6.54 \pm 1.42 (79 \pm 11)DLCO, VA (mmol/min/kPa/L)1.18 \pm 0.23 (81 \pm 14)2.17 \pm 1.15 (86 \pm 11)Pes Sniff, cmH_2O-67 \pm 18-73 \pm 17MIP, cmH_2O132 \pm 42130 \pm 49Echocardiogram112 \pm 6-LVEF, %31 \pm 6-LVEF, %31 \pm 6-LV end-diastolic diameter, cm6.4 \pm 0.6-LV end-diastolic cidameter, cm6.4 \pm 0.6-LV end-diastolic cidameter, cm6.4 \pm 0.6- <t< td=""><td>Medication, n (%)</td><td></td><td></td></t<>	Medication, n (%)				
Angiotensin II receptor antagonist4 (25)1 (6)Aldosterone receptor antagonist9 (56)0 (0)°Diuretics10 (63)0 (0)°Pulmonary FunctionFEV1, L (% pred)2.52 \pm 0.74 (82 \pm 19)2.81 \pm 0.56 (98 \pm 8)°FVC, L (% pred)3.08 \pm 0.88 (79 \pm 16)3.48 \pm 0.70 (97 \pm 8)°FEV1/FVC, (%)82 \pm 781 \pm 2FEV1/FVC, (%)81 \pm 879 \pm 2FEF21/SVC, (%)81 \pm 879 \pm 2FEF24/SVC, (%)81 \pm 879 \pm 2FE724/SVC, (%)9102.54 \pm 0.81 (87 \pm 18)2.60 \pm 0.53 (102 \pm 24)°2.64 \pm 0.81 (87 \pm 18)2.60 \pm 0.53 (102 \pm 24)°2.64 \pm 106 \pm 13°DLCO, (mmol/min/kPa)5.57 \pm 1.39 (67 \pm 11)DLCO, (mmol/min/kPa/L)1.18 \pm 0.23 (81 \pm 14)2.17 \pm 1.15 (86 \pm 11)Pes Snift, cmH2O-67 \pm 18MEP, cmH2O-76 \pm 28MEP, cmH2O113 \pm 42 <td< td=""><td>Beta-blockers</td><td>15 (94)</td><td>1 (6)*</td></td<>	Beta-blockers	15 (94)	1 (6)*		
Adosterone receiver antagonist9 (56)0 (0)Diuretics10 (63)0 (0)Pulmonary Function $EEV_1, L (\% pred)$ $2.52 \pm 0.74 (82 \pm 19)$ $2.81 \pm 0.56 (98 \pm 8)^{\circ}$ FVC, L (% pred) $3.08 \pm 0.88 (79 \pm 16)$ $3.48 \pm 0.70 (97 \pm 8)^{\circ}$ FEV_1/FVC, (%) 82 ± 7 81 ± 2 FEV_5VC, (%) 81 ± 8 79 ± 2 FEF25=75%, Ls ⁻¹ (% pred) $2.54 \pm 0.97 (83 \pm 39)$ $2.65 \pm 0.65 (98 \pm 15)$ TLC, L (% pred) $2.54 \pm 0.97 (83 \pm 23)$ $3.54 \pm 0.71 (105 \pm 7)^{\circ}$ SVC, L (% pred) $2.54 \pm 0.81 (87 \pm 18)$ $2.60 \pm 0.53 (102 \pm 24)^{\circ}$ FRC, L (% pred) $2.94 \pm 0.67 (91 \pm 18)$ $3.01 \pm 0.54 (77 \pm 46)$ RV, L (% pred) $2.38 \pm 0.64 (130 \pm 38)$ $2.09 \pm 0.44 (90 \pm 63)^{\circ}$ RV/TLC, (% pred) $1.18 \pm 0.23 (81 \pm 14)$ $2.17 \pm 1.15 (86 \pm 11)$ DLCO, (mmol/min/kPa/L) $1.18 \pm 0.23 (81 \pm 14)$ $2.17 \pm 1.15 (86 \pm 11)$ Pes Snift, cmH ₂ O -76 ± 28 -97 ± 16 MEP, cmH ₂ O 113 ± 42 130 ± 49 Echocardiogram 118 ± 0.66 $-102 + 102 +$	Angiotensin-converting enzyme inhibitors	10 (63)	0 (0)*		
Diuretics $10 (63)$ $0 (0)^{\circ}$ Pulmonary FunctionFEV1, L (% pred) $2.52 \pm 0.74 (82 \pm 19)$ $2.81 \pm 0.56 (98 \pm 8)^{\circ}$ FVC, L (% pred) $3.08 \pm 0.88 (79 \pm 16)$ $3.48 \pm 0.70 (97 \pm 8)^{\circ}$ FEV1/FVC, (%) 82 ± 7 81 ± 2 FEV1/SVC, (%) 81 ± 8 79 ± 2 FEF25.75% L $s^{-1} (\% pred)$ $2.54 \pm 0.97 (83 \pm 39)$ $2.65 \pm 0.65 (98 \pm 15)$ TLC, L (% pred) $5.48 \pm 1.27 (96 \pm 15)$ $5.76 \pm 0.81 (109 \pm 10)^{\circ}$ SVC, L (% pred) $3.10 \pm 0.95 (84 \pm 23)$ $3.54 \pm 0.71 (105 \pm 7)^{\circ}$ IC, L (% pred) $2.54 \pm 0.81 (87 \pm 18)$ $2.60 \pm 0.53 (102 \pm 24)^{\circ}$ FRC, L (% pred) $2.94 \pm 0.67 (91 \pm 18)$ $3.01 \pm 0.54 (77 \pm 46)$ RV, L (% pred) 129 ± 24 $106 \pm 13^{\circ}$ DLCO, (mmol/min/kPa) $5.57 \pm 1.39 (67 \pm 11)$ $6.54 \pm 1.42 (79 \pm 11)$ DLCO, VA (mmol/min/kPa/L) $1.18 \pm 0.23 (81 \pm 14)$ $2.17 \pm 1.15 (86 \pm 11)$ Pes Sniff, cmH ₂ O -76 ± 28 -97 ± 16 MEP, cmH ₂ O 113 ± 42 130 ± 49 Echocardiogram 113 ± 42 130 ± 49 LVEF, % 31 ± 6 -1 LV end-diastolic diameter, cm 6.4 ± 0.6 -1 LV end-diastolic diameter, cm 6.4 ± 0.6 -1 LV end-diastolic diameter, cm 275.7 ± 59.9 -1 PSAP, mmHg 32.6 ± 8.3 -1	Angiotensin II receptor antagonist	4 (25)	1 (6)		
Pulmonary FunctionFEV1, L (% pred) $2.52 \pm 0.74 (82 \pm 19)$ $2.81 \pm 0.56 (98 \pm 8)^{\circ}$ FVC, L (% pred) $3.08 \pm 0.88 (79 \pm 16)$ $3.48 \pm 0.70 (97 \pm 8)^{\circ}$ FEV1/FVC, (%) 82 ± 7 81 ± 2 FEV1/SVC, (%) 81 ± 8 79 ± 2 FEF25.75%, L.S ⁻¹ (% pred) $2.54 \pm 0.97 (83 \pm 39)$ $2.65 \pm 0.65 (98 \pm 15)$ TLC, L (% pred) $5.48 \pm 1.27 (96 \pm 15)$ $5.76 \pm 0.81 (109 \pm 10)^{\circ}$ SVC, L (% pred) $3.10 \pm 0.95 (84 \pm 23)$ $3.54 \pm 0.71 (105 \pm 7)^{\circ}$ IC, L (% pred) $2.54 \pm 0.81 (87 \pm 18)$ $2.60 \pm 0.53 (102 \pm 24)^{\circ}$ FRC, L (% pred) $2.94 \pm 0.67 (91 \pm 18)$ $3.01 \pm 0.54 (77 \pm 46)$ RV, L (% pred) 129 ± 24 $106 \pm 13^{\circ}$ DLCO, (mol/min/kPa) $5.75 \pm 1.39 (67 \pm 11)$ $6.54 \pm 1.42 (79 \pm 11)$ DLCO, VA (mmol/min/kPa/L) $1.18 \pm 0.23 (81 \pm 14)$ $2.17 \pm 1.15 (86 \pm 11)$ Pes Sniff, cmH2O -76 ± 28 -97 ± 16 MEP, cmH2O 113 ± 42 130 ± 49 Echocardiogram $2.08.7 \pm 44.5$ $-$ LVEF, % 31 ± 6 $-$ LV end-diastolic volume, mL 208.7 ± 44.5 $-$ LV end-diastolic volume, mL 208.7 ± 49.5 $-$ LV end-diastolic diameter, cm 6.4 ± 0.6 $-$ LV mad, s, g 275.7 ± 59.9 $-$ PSAP, mmHg 32.6 ± 8.3 $-$	Aldosterone receptor antagonist	9 (56)	0 (0)*		
FEV1, L (% pred) $2.52 \pm 0.74 (82 \pm 19)$ $2.81 \pm 0.56 (98 \pm 8)^{\circ}$ FVC, L (% pred) $3.08 \pm 0.88 (79 \pm 16)$ $3.48 \pm 0.70 (97 \pm 8)^{\circ}$ FEV1,/FVC, (%) 82 ± 7 81 ± 2 FEV1/SVC, (%) 81 ± 8 79 ± 2 FEF25.75%, L.S ⁻¹ (% pred) $2.54 \pm 0.97 (83 \pm 39)$ $2.65 \pm 0.65 (98 \pm 15)$ TLC, L (% pred) $5.48 \pm 1.27 (96 \pm 15)$ $5.76 \pm 0.81 (109 \pm 10)^{\circ}$ SVC, L (% pred) $3.10 \pm 0.95 (84 \pm 23)$ $3.54 \pm 0.71 (105 \pm 7)^{\circ}$ IC, L (% pred) $2.54 \pm 0.81 (87 \pm 18)$ $2.60 \pm 0.53 (102 \pm 24)^{\circ}$ FRC, L (% pred) $2.94 \pm 0.67 (91 \pm 18)$ $3.01 \pm 0.54 (77 \pm 46)$ RV/LC, (% pred) $2.38 \pm 0.64 (130 \pm 38)$ $2.09 \pm 0.44 (90 \pm 63)^{\circ}$ RV/TLC, (% pred) 129 ± 24 $106 \pm 13^{\circ}$ DLCO, (mmol/min/kPa) $1.18 \pm 0.23 (81 \pm 14)$ $2.17 \pm 1.15 (86 \pm 11)$ Pes Sniff, cmH ₂ O -67 ± 18 -73 ± 17 MIP, cmH ₂ O 113 ± 42 130 ± 49 Echocardiogram 208.7 ± 44.5 -10.64 ± 1.42 LVEF, % 31 ± 6 -1 LV end-diastolic volume, mL 208.7 ± 44.5 -1 LV end-diastolic diameter, cm 6.4 ± 0.6 -1 LV mass, g 275.7 ± 59.9 -1 PSAP, mmHg 32.6 ± 8.3 -1	Diuretics	10 (63)	0 (0)*		
FVC, L (% pred) $3.08 \pm 0.88 (79 \pm 16)$ $3.48 \pm 0.70 (97 \pm 8)^{\circ}$ FEV1/FVC, (%) 82 ± 7 81 ± 2 FEV1/SVC, (%) 81 ± 8 79 ± 2 FEF25-75%, L.s ⁻¹ (% pred) $2.54 \pm 0.97 (83 \pm 39)$ $2.65 \pm 0.65 (98 \pm 15)$ TLC, L (% pred) $5.48 \pm 1.27 (96 \pm 15)$ $5.76 \pm 0.81 (109 \pm 10)^{\circ}$ SVC, L (% pred) $3.10 \pm 0.95 (84 \pm 23)$ $3.54 \pm 0.71 (105 \pm 7)^{\circ}$ IC, L (% pred) $2.54 \pm 0.81 (87 \pm 18)$ $2.60 \pm 0.53 (102 \pm 24)^{\circ}$ FRC, L (% pred) $2.94 \pm 0.67 (91 \pm 18)$ $3.01 \pm 0.54 (77 \pm 46)$ RV, L (% pred) $2.38 \pm 0.64 (130 \pm 38)$ $2.09 \pm 0.44 (90 \pm 63)^{\circ}$ RV/TLC, (% pred) 129 ± 24 $106 \pm 13^{\circ}$ DLCO, (mmol/min/kPa) $1.18 \pm 0.23 (81 \pm 14)$ $2.17 \pm 1.15 (86 \pm 11)$ Pes Sniff, cmH ₂ O -67 ± 18 -73 ± 17 MIP, cmH ₂ O 113 ± 42 130 ± 49 Echocardiogram 208.7 ± 44.5 $-$ LVEF, % 31 ± 6 $-$ LV end-diastolic volume, mL 208.7 ± 44.5 $-$ LV end-diastolic diameter, cm 6.4 ± 0.6 $-$ LV mass, g 275.7 ± 59.9 $-$ PSAP, mmHg 32.6 ± 8.3 $-$	Pulmonary Function				
FEV1/FVC, (%) 82 ± 7 81 ± 2 FEV1/SVC, (%) 81 ± 8 79 ± 2 FEF25-75%, L.S ⁻¹ (% pred) 2.54 ± 0.97 (83 ± 39) 2.65 ± 0.65 (98 ± 15)TLC, L (% pred) 5.48 ± 1.27 (96 ± 15) 5.76 ± 0.81 ($109 \pm 10^{\circ}$)SVC, L (% pred) 3.10 ± 0.95 (84 ± 23) 3.54 ± 0.71 (105 ± 7)IC, L (% pred) 2.54 ± 0.81 (87 ± 18) 2.60 ± 0.53 (102 ± 24)*FRC, L (% pred) 2.94 ± 0.67 (91 ± 18) 3.01 ± 0.54 (77 ± 46)RV, L (% pred) 2.38 ± 0.64 (130 ± 38) 2.09 ± 0.44 (90 ± 63)*RV/TLC, (% pred) 129 ± 24 $106 \pm 13^{*}$ DLCO, (mmol/min/kPa) 5.57 ± 1.39 (67 ± 11) 6.54 ± 1.42 (79 ± 11)DLCO/VA (mmol/min/kPa) 1.18 ± 0.23 (81 ± 14) 2.17 ± 1.15 (86 ± 11)Pes Sniff, cmH2O -67 ± 18 -73 ± 17 MIP, cmH2O 113 ± 42 130 ± 49 208.7 ± 44.5 $-$ LVEF, % 31 ± 6 $-$ LV end-diastolic diameter, cm 6.4 ± 0.6 $-$ LV mass, g 275.7 ± 59.9 $-$ PSAP, mmHg 32.6 ± 8.3 $-$	FEV ₁ , L (% pred)	$2.52 \pm 0.74 (82 \pm 19)$	$2.81 \pm 0.56 (98 \pm 8)^{*}$		
FEV1/SVC, (%) 81 ± 8 79 ± 2 FEF25.75%, Ls ⁻¹ (% pred) $2.54 \pm 0.97 (83 \pm 39)$ $2.65 \pm 0.65 (98 \pm 15)$ TLC, L (% pred) $5.48 \pm 1.27 (96 \pm 15)$ $5.76 \pm 0.81 (109 \pm 10)^{*}$ SVC, L (% pred) $3.10 \pm 0.95 (84 \pm 23)$ $3.54 \pm 0.71 (105 \pm 7)^{*}$ IC, L (% pred) $2.54 \pm 0.81 (87 \pm 18)$ $2.60 \pm 0.53 (102 \pm 24)^{*}$ FRC, L (% pred) $2.94 \pm 0.67 (91 \pm 18)$ $3.01 \pm 0.54 (77 \pm 46)$ RV, L (% pred) $2.38 \pm 0.64 (130 \pm 38)$ $2.09 \pm 0.44 (90 \pm 63)^{*}$ RV/TLC, (% pred) 129 ± 24 $106 \pm 13^{*}$ DLCO, (mmol/min/kPa) $5.57 \pm 1.39 (67 \pm 11)$ $6.54 \pm 1.42 (79 \pm 11)$ DLCO/VA (mmol/min/kPa/L) $1.18 \pm 0.23 (81 \pm 14)$ $2.17 \pm 1.15 (86 \pm 11)$ Pes Sniff, cmH ₂ O -67 ± 18 -73 ± 17 MIP, cmH ₂ O 113 ± 42 130 ± 49 EchocardiogramLVEF, % 31 ± 6 $-$ LVEF, % 31 ± 6 $-$ LV end-diastolic volume, mI. 208.7 ± 44.5 $-$ LV mass, g 275.7 ± 59.9 $-$ PSAP, mmHg 32.6 ± 8.3 $-$	FVC, L (% pred)	$3.08 \pm 0.88 (79 \pm 16)$	$3.48 \pm 0.70 (97 \pm 8)^{*}$		
$FEF_{25-75\%}$, Ls^{-1} (% pred) 2.54 ± 0.97 (83 ± 39) 2.65 ± 0.65 (98 ± 15)TLC, L (% pred) 5.48 ± 1.27 (96 ± 15) 5.76 ± 0.81 (109 ± 10)°SVC, L (% pred) 3.10 ± 0.95 (84 ± 23) 3.54 ± 0.71 (105 ± 7)°IC, L (% pred) 2.54 ± 0.81 (87 ± 18) 2.60 ± 0.53 (102 ± 24)°FRC, L (% pred) 2.94 ± 0.67 (91 ± 18) 3.01 ± 0.54 (77 ± 46)RV, L (% pred) 2.38 ± 0.64 (130 ± 38) 2.09 ± 0.44 (90 ± 63)°RV/TLC, (% pred) 129 ± 24 $106 \pm 13^{\circ}$ DLCO, (mmol/min/kPa) 5.57 ± 1.39 (67 ± 11) 6.54 ± 1.42 (79 ± 11)DLCO/VA (mmol/min/kPa) 1.18 ± 0.23 (81 ± 14) 2.17 ± 1.15 (86 ± 11)Pes Sniff, cmH_2O -67 ± 18 -73 ± 17 MIP, cmH_2O -76 ± 28 -97 ± 16 MEP, cmH_2O 113 ± 42 130 ± 49 LVEF, %LVEF, % 31 ± 6 $-$ LV end-diastolic volume, mL 208.7 ± 44.5 $-$ LV mass, g 275.7 ± 59.9 $-$ PSAP, mmHg 32.6 ± 8.3 $-$	FEV ₁ /FVC, (%)	82 ± 7	81 ± 2		
TLC, L (% pred) $5.48 \pm 1.27 (96 \pm 15)$ $5.76 \pm 0.81 (109 \pm 10)^{*}$ SVC, L (% pred) $3.10 \pm 0.95 (84 \pm 23)$ $3.54 \pm 0.71 (105 \pm 7)^{*}$ IC, L (% pred) $2.54 \pm 0.81 (87 \pm 18)$ $2.60 \pm 0.53 (102 \pm 24)^{*}$ FRC, L (% pred) $2.94 \pm 0.67 (91 \pm 18)$ $3.01 \pm 0.54 (77 \pm 46)$ RV, L (% pred) $2.38 \pm 0.64 (130 \pm 38)$ $2.09 \pm 0.44 (90 \pm 63)^{*}$ RV/LC, (% pred) 129 ± 24 $106 \pm 13^{*}$ DLCO, (mmol/min/kPa) $5.57 \pm 1.39 (67 \pm 11)$ $6.54 \pm 1.42 (79 \pm 11)$ DLCO/VA (mmol/min/kPa) $1.18 \pm 0.23 (81 \pm 14)$ $2.17 \pm 1.15 (86 \pm 11)$ Pes Sniff, cmH ₂ O -67 ± 18 -73 ± 17 MIP, cmH ₂ O -76 ± 28 -97 ± 16 MEP, cmH ₂ O 113 ± 42 130 ± 49 EchocardiogramLVEF, % 31 ± 6 $-$ LV end-diastolic diameter, cm 6.4 ± 0.6 $-$ LV end-diastolic diameter, cm 6.4 ± 0.6 $-$ LV mass, g 275.7 ± 59.9 $-$ PSAP, mmHg 32.6 ± 8.3 $-$		81 ± 8	79 ± 2		
SVC, L (% pred) $3.10 \pm 0.95 (84 \pm 23)$ $3.54 \pm 0.71 (105 \pm 7)^{\circ}$ IC, L (% pred) $2.54 \pm 0.81 (87 \pm 18)$ $2.60 \pm 0.53 (102 \pm 24)^{\circ}$ FRC, L (% pred) $2.94 \pm 0.67 (91 \pm 18)$ $3.01 \pm 0.54 (77 \pm 46)$ RV, L (% pred) $2.38 \pm 0.64 (130 \pm 38)$ $2.09 \pm 0.44 (90 \pm 63)^{\circ}$ RV/LC, (% pred) 129 ± 24 $106 \pm 13^{\circ}$ DLCO, (mmol/min/kPa) $5.57 \pm 1.39 (67 \pm 11)$ $6.54 \pm 1.42 (79 \pm 11)$ DLCO/VA (mmol/min/kPa/L) $1.18 \pm 0.23 (81 \pm 14)$ $2.17 \pm 1.15 (86 \pm 11)$ Pes Sniff, cmH ₂ O -67 ± 18 -73 ± 17 MIP, cmH ₂ O 113 ± 42 130 ± 49 EchocardiogramLVEF, % 31 ± 6 $-$ LV end-diastolic volume, mL 208.7 ± 44.5 $-$ LV end-diastolic diameter, cm 6.4 ± 0.6 $-$ LV mass, g 275.7 ± 59.9 $-$ PSAP, mmHg 32.6 ± 8.3 $-$	$\text{FEF}_{25-75\%}$, L.s ⁻¹ (% pred)	$2.54 \pm 0.97 (83 \pm 39)$	$2.65 \pm 0.65 (98 \pm 15)$		
IC, L (% pred) $2.54 \pm 0.81 (87 \pm 18)$ $2.60 \pm 0.53 (102 \pm 24)^*$ FRC, L (% pred) $2.94 \pm 0.67 (91 \pm 18)$ $3.01 \pm 0.54 (77 \pm 46)$ RV, L (% pred) $2.38 \pm 0.64 (130 \pm 38)$ $2.09 \pm 0.44 (90 \pm 63)^*$ RV/TLC, (% pred) 129 ± 24 $106 \pm 13^*$ DLCO, (mmol/min/kPa) $5.57 \pm 1.39 (67 \pm 11)$ $6.54 \pm 1.42 (79 \pm 11)$ DLCO, VA (mmol/min/kPa/L) $1.18 \pm 0.23 (81 \pm 14)$ $2.17 \pm 1.15 (86 \pm 11)$ Pes Sniff, cmH ₂ O -67 ± 18 -73 ± 17 MIP, cmH ₂ O -76 ± 28 -97 ± 16 MEP, cmH ₂ O 113 ± 42 130 ± 49 EchocardiogramLVEF, % 31 ± 6 $-$ LV end-diastolic volume, mL 208.7 ± 44.5 $-$ LV end-diastolic diameter, cm 6.4 ± 0.6 $-$ LV mas, g 275.7 ± 59.9 $-$ PSAP, mmHg 32.6 ± 8.3 $-$	TLC, L (% pred)	5.48 ± 1.27 (96 ± 15)	$5.76 \pm 0.81 (109 \pm 10)^{*}$		
FRC, L (% pred) $2.94 \pm 0.67 (91 \pm 18)$ $3.01 \pm 0.54 (77 \pm 46)$ RV, L (% pred) $2.38 \pm 0.64 (130 \pm 38)$ $2.09 \pm 0.44 (90 \pm 63)^{\circ}$ RV/TLC, (% pred) 129 ± 24 $106 \pm 13^{\circ}$ DLCO, (mmol/min/kPa) $5.57 \pm 1.39 (67 \pm 11)$ $6.54 \pm 1.42 (79 \pm 11)$ DLCO/VA (mmol/min/kPa) $1.18 \pm 0.23 (81 \pm 14)$ $2.17 \pm 1.15 (86 \pm 11)$ Pes Snift, cmH ₂ O -67 ± 18 -73 ± 17 MIP, cmH ₂ O -76 ± 28 -97 ± 16 MEP, cmH ₂ O 113 ± 42 130 ± 49 EchocardiogramLVEF, % 31 ± 6 $-$ LV end-diastolic volume, mL 208.7 ± 44.5 $-$ LV mass, g 275.7 ± 59.9 $-$ PSAP, mmHg 32.6 ± 8.3 $-$	SVC, L (% pred)	3.10 ± 0.95 (84 ± 23)	$3.54 \pm 0.71 (105 \pm 7)^{*}$		
RV, L (% pred) $2.38 \pm 0.64 (130 \pm 38)$ $2.09 \pm 0.44 (90 \pm 63)^*$ RV/TLC, (% pred) 129 ± 24 $106 \pm 13^*$ DLCO, (mmol/min/kPa) $5.57 \pm 1.39 (67 \pm 11)$ $6.54 \pm 1.42 (79 \pm 11)$ DLCO/VA (mmol/min/kPa) $1.18 \pm 0.23 (81 \pm 14)$ $2.17 \pm 1.15 (86 \pm 11)$ Pes Sniff, cmH ₂ O -67 ± 18 -73 ± 17 MIP, cmH ₂ O -76 ± 28 -97 ± 16 MEP, cmH ₂ O 113 ± 42 130 ± 49 EchocardiogramLVEF, % 31 ± 6 $-$ LV end-diastolic volume, mL 208.7 ± 44.5 $-$ LV end-diastolic diameter, cm 6.4 ± 0.6 $-$ LV mass, g 275.7 ± 59.9 $-$ PSAP, mmHg 32.6 ± 8.3 $-$	IC, L (% pred)	$2.54 \pm 0.81 (87 \pm 18)$	$2.60 \pm 0.53 (102 \pm 24)^{*}$		
RV/TLC, (0 pred)129 ± 24106 ± 13°DLCO, (mmol/min/kPa)5.57 ± 1.39 (67 ± 11)6.54 ± 1.42 (79 ± 11)DLCO/VA (mmol/min/kPa)L)1.18 ± 0.23 (81 ± 14)2.17 ± 1.15 (86 ± 11)Pes Sniff, cmH_2O-67 ± 18-73 ± 17MIP, cmH_2O-76 ± 28-97 ± 16MEP, cmH_2O113 ± 42130 ± 49EchocardiogramLVEF, %31 ± 6-LV end-diastolic volume, mL208.7 ± 44.5-LV end-diastolic diameter, cm6.4 ± 0.6-LV mass, g275.7 ± 59.9-PSAP, mmHg32.6 ± 8.3-	FRC, L (% pred)	$2.94 \pm 0.67 (91 \pm 18)$			
$ \begin{array}{llllllllllllllllllllllllllllllllllll$					
$ \begin{array}{llllllllllllllllllllllllllllllllllll$	RV/TLC, (% pred)				
Pes Sniff, cmH ₂ O -67 ± 18 -73 ± 17 MIP, cmH ₂ O -76 ± 28 -97 ± 16 MEP, cmH ₂ O 113 ± 42 130 ± 49 Echocardiogram 113 ± 6 $-$ LVEF, % 31 ± 6 $-$ LV end-diastolic volume, mL 208.7 ± 44.5 $-$ LV end-diastolic diameter, cm 6.4 ± 0.6 $-$ LV mass, g 275.7 ± 59.9 $-$ PSAP, mmHg 32.6 ± 8.3 $-$. ,	6.54 ± 1.42 (79 ± 11)		
MIP, cmH ₂ O -76 ± 28 -97 ± 16 MEP, cmH ₂ O 113 ± 42 130 ± 49 Echocardiogram	DLCO/VA (mmol/min/kPa/L)	$1.18 \pm 0.23 (81 \pm 14)$			
MEP, cmH ₂ O 113 ± 42 130 ± 49 Echocardiogram	-				
Echocardiogram 31 ± 6 - LVEF, % 31 ± 6 - LV end-diastolic volume, mL 208.7 ± 44.5 - LV end-diastolic diameter, cm 6.4 ± 0.6 - LV mass, g 275.7 ± 59.9 - PSAP, mmHg 32.6 ± 8.3 -					
LVEF, % 31 ± 6 - LV end-diastolic volume, mL 208.7 ± 44.5 - LV end-diastolic diameter, cm 6.4 ± 0.6 - LV mass, g 275.7 ± 59.9 - PSAP, mmHg 32.6 ± 8.3 -	MEP, cmH ₂ O	113 ± 42	130 ± 49		
LV end-diastolic volume, mL 208.7 ± 44.5 - LV end-diastolic diameter, cm 6.4 ± 0.6 - LV mass, g 275.7 ± 59.9 - PSAP, mmHg 32.6 ± 8.3 -					
LV end-diastolic diameter, cm 6.4 ± 0.6 - LV mass, g 275.7 \pm 59.9 - PSAP, mmHg 32.6 ± 8.3 -			-		
LV mass, g 275.7 ± 59.9 - PSAP, mmHg 32.6 ± 8.3 -	-		-		
PSAP, mmHg 32.6 ± 8.3 –			-		
			-		
KV diameter, cm 2.2 ± 0.4 –			-		
	KV diameter, cm	2.2 ± 0.4	-		

Values are means \pm SD or number (%).

Abbreviations;: CHF = chronic heart failure; BMI = body mass index; MRC = medical research council; NYHA = New York Heart Association; % pred = percentage of predicted values; FEV_1 = forced expired volume in 1 s; FVC = forced vital capacity; SVC = slow vital capacity; $FEF_{25-75\%}$ = forced expiratory flow at 25–75% of forced vital capacity; TLC = total lung capacity; IC = inspiratory capacity; FRC = functional residual capacity; RV = residual volume; DLCO = diffusing capacity of the lung for carbon monoxide; DLCO/VA = DLCO corrected for alveolar volume; Pes Sniff = maximum inspiratory esophageal pressure during Sniff maneuver; MIP = maximal inspiratory mouth pressure; MEP = maximal expiratory mouth pressure; LVEF = left ventricular ejection fraction; LV = Left ventricle; PSAP = pulmonary systolic arterial pressure; RV = right ventricle.

* p < .05.

^a Data related to one subject.

2.2. Procedures

The participants performed resting pulmonary function tests and symptom-limited cycle (Corival^{*}, Lode, Groningen, Netherlands) incremental (5–10 W/min) cardiopulmonary exercise test (Vmax Encore^{*}, CareFusion, Yorba Linda, USA) with serial measurements of IC (Guenette et al., 2013). Prior to testing, subjects were familiarized with the technique for performing IC measurement. After 4 stable tidal breaths, subjects received a verbal prompt to begin the maneuver ("at

the end of the next normal breath out, breathe all the way in") and then verbal encouragement to make a maximal effort and hold the breath for, at least, 1s before relaxing back to pre-maneuver breathing. In general, two reproducible IC maneuvers (i.e., within 10% of the largest acceptable value) were performed at rest, 2-min intervals thereafter and at the end of exercise. A reduction in IC was defined as a peak exerciserest difference of more than 150 mL. Symptom intensity was inquired before IC maneuvers. Esophageal (Pes) pressure was obtained using thin-walled balloon catheters (Ackrad[®], Laboratories Inc, USA) coupled Download English Version:

https://daneshyari.com/en/article/8650787

Download Persian Version:

https://daneshyari.com/article/8650787

Daneshyari.com